OSTX logo

OS Therapies Incorporated

OSTX
Healthcare|Biotechnology|US
$1.00
+0.02 (+2.03%)
Cash / Share
$0.00
Next Earnings Report
Nov 13, 2026
EPS est. -$0.13 · Revenue est. $1.0M
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Sep 10, 2026 (424B7). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial
Nov 5, 2026 · Newsfile Corp
OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million
Oct 19, 2026 · Newsfile Corp
Rubenstein Public Relations Named Agency of Record for OS Therapies
Oct 8, 2026 · GlobeNewsWire
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
Oct 7, 2026 · Newsfile Corp
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
Oct 6, 2026 · Newsfile Corp
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Oct 1, 2026 · Newsfile Corp
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
Sep 24, 2026 · Newsfile Corp
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
Sep 21, 2026 · Newsfile Corp
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
Sep 17, 2026 · Newsfile Corp
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
Sep 15, 2026 · Newsfile Corp

SEC Filings (101)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 23, 2026DDocumentIndex
Oct 19, 20268-KMaterial eventDocumentIndex
Oct 5, 20268-KMaterial eventDocumentIndex
Sep 21, 2026S-8Employee stock planDocumentIndex
Sep 10, 20268-KMaterial eventDocumentIndex
Sep 10, 2026424B7Offering prospectusDocumentIndex
Sep 9, 20268-KMaterial eventDocumentIndex
Aug 25, 2026DDocumentIndex
Aug 21, 20268-KMaterial eventDocumentIndex
Aug 21, 2026424B5Offering prospectusDocumentIndex
Aug 14, 202610-QQuarterly reportDocumentIndex
Aug 12, 20268-KMaterial eventDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Aug 6, 2026424B5Offering prospectusDocumentIndex
Jul 29, 20268-KMaterial eventDocumentIndex
Jul 24, 2026ARSAnnual report to holdersDocumentIndex
Jul 24, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jul 24, 2026DEF 14AProxy / shareholder voteDocumentIndex
Jul 16, 2026DDocumentIndex
Jul 7, 20268-K/AMaterial eventDocumentIndex
Jul 2, 20268-KMaterial eventDocumentIndex
May 18, 202610-QQuarterly reportDocumentIndex
May 15, 2026NT 10-QDocumentIndex
Apr 30, 20268-KMaterial eventDocumentIndex
Apr 2, 20268-KMaterial eventDocumentIndex
Apr 2, 2026424B5Offering prospectusDocumentIndex
Mar 31, 20268-KMaterial eventDocumentIndex
Mar 31, 2026424B7Offering prospectusDocumentIndex
Mar 31, 202610-KAnnual reportDocumentIndex
Mar 6, 2026DDocumentIndex
Mar 6, 20268-KMaterial eventDocumentIndex
Feb 13, 20268-KMaterial eventDocumentIndex
Jan 20, 2026DDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Nov 14, 202510-QQuarterly reportDocumentIndex
Oct 31, 2025S-8Employee stock planDocumentIndex
Oct 21, 20258-KMaterial eventDocumentIndex
Oct 17, 2025DEFA14AProxy / shareholder voteDocumentIndex
Oct 17, 20258-KMaterial eventDocumentIndex
Sep 30, 20258-KMaterial eventDocumentIndex